- Allogene completed a $300 Million Series A round in April of 2018
- Investors in the Series A round included Gilead and Pfizer
Allogene Therapeutics, Inc., a clinical-... read more
Allogene Therapeutics, Inc., a clinical-... read more
EpicGenetics announced on9/5/18 that the U.S. Food and Drug Administration (FDA) has given approval to the Massachusetts General Hospital for a human clinical trial of BCG (an inexpensive generic... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,